The utilization of 3-month adjuvant chemotherapy significantly increased between the time the IDEA abstract was given and the time the full report was published.
The IDEA study, a comprehensive analysis of six randomized phase 3 trials, has significantly influenced the prescribing of adjuvant therapy for stage III colon cancer. The study aimed to determine if the duration of adjuvant therapy could be reduced from 6 months to 3 months, and the findings have led to changes in real-world prescribing patterns.
- The IDEA study evaluated reducing adjuvant therapy from 6 to 3 months using FOLFOX or CAPOX.
- The 3-month treatment was not noninferior to the 6-month treatment overall (HR, 1.07; 95% CI, 1.00-1.15).
- 3 months of CAPOX was noninferior to 6 months, but not for FOLFOX (HR, 1.16; 95% CI, 1.06-1.26).
- The analysis included 399 patients, with a significant increase in the use of 3-month treatment from 5.6% to 45.2% after the IDEA manuscript was published.
- The use of adjuvant FOLFOX decreased from 86.0% to 52.0%, while CAPOX increased from 14.0% to 48.0%.
- The transition toward 3 months of chemotherapy was adopted earlier in Black patients than in White patients.
- The researchers plan to evaluate clinical outcomes in a follow-up study, including outcomes associated with oxaliplatin discontinuation.
- Despite failing to demonstrate noninferiority of 3 months’ duration, the IDEA study has influenced practice, favoring CAPOX and a shorter duration of planned adjuvant treatment.